The Bayer DCA 2000 + is a fully automated chemical analyzers. It is often the most workable choice to acquire results for hemoglobin A1c and microalbumin/creatinine tests in minutes. The manufacturer of this point-of-care diabetes management platform is Bayer Diagnostics (a division of Siemens).
- Proven to provide accurate and precise lab-quality results.
- Barcode patient data entry to reduce transcription errors.
Enhanced productivity:
- Onboard printed results; eliminates transcription errors and saves time.
- Automatically uploads results to a LIS/HIS.
- Largest memory stores up to 4000 records; easily downloaded and transferred to a PC.
- Add sample to test cartridge, load, and walk away.
- No sample or reagent preparation.
- Color touch screen display; easier menu navigation, data entry and recall.
- Minimal maintenance required with automatic reminders.
- Totally self-contained reagent cartridges — no reagent preparation, mixing or handling
- Sample collection capillary holder is an integral part of unique reagent cartridge
- No costly, time-consuming calibration — factory-calibrated instrument eliminates all wet calibrations
- Screen displays all instructions, calibration status and testing information and results
- Up to 16 results stored in memory for convenient recordkeeping
Laboratory-accurate results just minutes after testing
- Review during patient visit, adjust blood glucose control regimen as appropriate
- Conforms with current guidelines for effective management
HbA1c results…in minutes
- Guide and reinforce your patients to maintain target blood glucose levels
- Quantitative HbA1c value in 6 minutes from capillary blood Low cost per test
- Monoclonal antibody method provides outstanding accuracy and precision
- Correlation study shows 99% agreement with the HPLC method
- Coefficients of variation <5% show excellent precision
Microalbumin/Creatinine ratio…in minutes
- In IDDM (insulin-dependent diabetes mellitus) patients, intensive insulin treatment:
- Delays the onset and slows the progression of microvascular complications
- Produces significant financial savings when part of long-term monitoring and control
- One reagent cartridge provides results for both microalbumin and creatinine as well as an automatic calculation of the albumin-to-creatinine ratio
- Quantitative results and calculated ratio displayed within 7 minutes using random urine sample.
Intensive management improves glycemic control
- Maintaining average blood glucose levels (120 mg/dL; 6.7 mmol/L; HbA1c 6%) lowers risk of complications.
- Three- to four-times-daily blood glucose monitoring is recommended.
- Establish and follow a coherent approach of combined nutritional counseling, self-management training and possible hospitalization for therapy initiation.
Reduce the risk. Monitor HbA1c levels
- HbA1c results monitor glucose control over the preceding 90 to 120 days.
- Complete normalization of glycemia levels may prevent complications.
- Quarterly HbA1c determination recommended for all insulin-treated patients.
- Recommendation also includes test for microalbuminuria and others, as indicated
Detect early stages of diabetic nephropathy. Protect your patient from complications
- Intensive diabetes management delays the onset of microalbuminuria -an early indicator of renal disease.
- Microalbumin-to-creatinine ratio from a random urine sample is as valid an indicator of microalbuminuria as a timed 24-hour sampling.
- Persistent microalbuminuria (30 to 300 mg/day) indicates the earliest stage of diabetic nephropathy.
- May also signal presence of hypertension and the need to begin antihypertensive therapy.
- Test for microalbuminuria should be performed yearly on postpubertal patients who have had diabetes for at least 5 years.
